350595-57-2

Basic information

• Product Name: 3S-3-METHYLMORPHOLINE
• Synonyms: 3S-3-METHYLMORPHOLINE;(S)-3-Methylmorpholine;(S)-3-MethylMorpholine HCl;Morpholine, 3-Methyl-, (3S)-;3S-3-Methylmorpholine(WX604204)
• CAS NO: 350595-57-2
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.15
• Product Categories: Amines;Heterocycles;Inhibitors
• Mol File: 350595-57-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 137.1 °C at 760 mmHg
• Flash Point: 41.3 °C
• Appearance: /
• Density: 0.891 g/cm³
• Vapor Pressure: 7.14mmHg at 25°C
• Refractive Index: 1.409
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.03±0.40(Predicted)
• CAS DataBase Reference: 3S-3-METHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3S-3-METHYLMORPHOLINE(350595-57-2)
• EPA Substance Registry System: 3S-3-METHYLMORPHOLINE(350595-57-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RIDADR: 2735
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 350595-57-2(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 350595-57-2 differently. You can refer to the following data:
1. (3S)-3-Methylmorpholine is useful in preparation of morpholinopyrimidine derivatives as mTOR kinase inhibitors for the treatment of diseases mediated by mTOR kinase and/or one or more PI3K enzymes
2. It is useful in preparation of morpholinopyrimidine derivatives as mTOR kinase inhibitors for the treatment of diseases mediated by mTOR kinase and/or one or more PI3K enzymes.

InChI:InChI=1/C5H11NO/c1-5-4-7-3-2-6-5/h5-6H,2-4H2,1H3/t5-/m0/s1

Upstream product

• 42185-06-8 3-methylmorpholine 
• 94193-79-0 2-chloro-N-((S)-2-hydroxy-1-methylethyl)acetamide 
• 119128-21-1 (5S)-5-methyl-4-(phenylmethyl)-3-morpholinone 
• 119844-66-5 (S)-5-methylmorpholin-3-one 
• 120800-91-1 (3S)-3-methyl-4-(phenylmethyl)morpholine 
• 634926-63-9 N-(tert-butyloxycarbonyl)-2-(propargyloxy)aminoethane 
• 122116-12-5 2-(prop-2-yn-1-yloxy)ethan-1-amine 

Downstream Products

• 944953-94-0 2-[(3S,4R,5R)-4-(4-methoxyphenyl)-5-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]-1-(toluene-4-sulfonyl)piperidin-3-yloxy]-1-((S)-3-methylmorpholin-4-yl)ethanone 
• 1260088-73-0 (S)-2-chloro-7,7-dimethyl-4-(3-methylmorpholino)-5,7-dihydrofuro[3,4-d]pyrimidine 
• 1542268-04-1 (S)-4-((4-(2-aminothiazol-5-yl)-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)oxy)-N,N-dimethylbenzamide hydrochloride 
• 1542268-00-7 C₂₀H₂₃N₇O₃S*CH₄O₃S 
• 1542268-11-0 C₃₂H₄₁N₇O₇ 
• 1542268-08-5 (S)-4-((4-(6-aminopyridin-3-yl)-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)oxy)-N,N-dimethylbenzamide hydrochloride 
• 1542268-17-6 C₂₄H₂₆FN₇O₄ 
• 1542267-11-7 (S)-4-((4-(6-aminopyridin-3-yl)-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)oxy)-3-fluoro-N,N-dimethylbenzamide 
• 1542268-12-1 (S)-4-((4-(6-aminopyridin-3-yl)-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)oxy)-3-fluoro-N,N-dimethylbenzamide hydrochloride 
• 1542268-21-2 C₂₅H₃₀FN₇O₅S 
• 1542268-18-7 4-(4-(2-aminothiazol-5-yl)-6-((S)-3-methylmorpholino)-1,3,5-triazin-2-yloxy)-3-fluoro-N,N-dimethylbenzamide hydrochloride 
• 1542268-10-9 C₁₇H₂₀ClN₅O₃ 
• 1542268-20-1 C₁₇H₁₉ClFN₅O₃ 
• 1101821-18-4 (S)-4-[2-chloro-6-((4-(difluoromethoxy)phenylsulfonyl)methyl)pyrimidin-4-yl]-3-methylmorpholine 

Relevant articles and documents

Acylative kinetic resolution of racemic methyl-substituted cyclic alkylamines with 2,5-dioxopyrrolidin-1-yl (: R)-2-phenoxypropanoate

The diastereoselective acylation of a number of racemic methyl-substituted cyclic alkylamines with active esters of 2-phenoxypropanoic acid was studied in detail. The ester of (R)-2-phenoxypropanoic acid and N-hydroxysuccinimide was found to be the most selective agent. The highest stereoselectivity was observed in the kinetic resolution of racemic 2-methylpiperidine in toluene at -40 °C (selectivity factor s = 73) with the predominant formation of (R,R)-amide (93.7% de). To explain the observed stereoselectivity, DFT modelling of the transition states in the reactions of the title acylating agent with 2-methylpiperidine and 2-methylpyrrolidine was performed. The calculated values were in good agreement with experimental data. It has been demonstrated that the acylation proceeds via a concerted mechanism, in which the addition of an amine occurs simultaneously with the elimination of the hydroxysuccinimide fragment. The high stereoselectivity of the (R,R)-amide formation is largely ensured by the lower steric hindrances in the transition states as compared to the formation of (R,S)-amide.

Preparation method of (S)-(4-bromine-2-methylbenzene) (3-N-methylmorpholine) ketone

The invention discloses a preparation method of (S)-(4-bromine-2-methylbenzene) (3-N-methylmorpholine) ketone, and belongs to the technical field of organic synthesis. The invention is characterized in that the preparation method of the (S)-(4-bromine-2-m

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway